mRNA Technology

The central focus of Pharmorage is the development of oligonucleotide technologies that modulate inflammation at its source.

In collaboration with Hudson Institute of Medical Research, Pharmorage is investigating ultra-short 3-base oligonucleotides (known as 3-mers) with the intention of reducing mRNA vaccine side effects through inhibiting TLR7 (Toll-like receptor 7). Pharmorage’s SOF-VAC asset is intended to enhance mRNA COVID vaccines, as well as future mRNA vaccines and therapeutics.

Pharmorage is a fully owned subsidiary of Noxopharm Limited. More information on the science and latest research can be found on the Noxopharm website.